In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
Type 1 diabetes onset before the age of 14 years is independently associated with a greater risk of kidney disease compared with later age at onset, according to a new study.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
Per the ADA update, clinicians should consider prescribing a SGLT2 inhibitor in type 2 diabetes patients with diabetic nephropathy.
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported
Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.